Acridine/Acridone-Carborane Conjugates as Strong DNA-Binding Agents with Anticancer Potential

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Biochemistry

Background:

• Acridine derivatives are investigated as DNA-targeting anticancer agents.
• Carboranes offer unique properties for designing biologically active compounds.

Purpose of the Study:

• To synthesize novel acridine analogs incorporating carborane clusters.
• To evaluate the DNA-binding properties and anticancer potential of these new compounds.

Main Methods:

• Synthesis of carborane-modified acridine analogs.
• Calf thymus DNA (ct-DNA) binding assays.
• Cytotoxicity, cell cycle arrest, reactive oxygen species (ROS) production, and subcellular localization studies in HeLa cancer cells.

Main Results:

• Compound 30 (9-[(1,7-dicarba-closo-dodecaborane-1-yl)propylamino]acridine) showed strong ct-DNA binding and intercalation.
• Compound 29 (9-[(1,7-dicarba-closo-dodecaborane-1-yl)propanamido]acridine) induced a B-to-Z DNA form transition.
• Compound 30 exhibited significant cytotoxicity, inhibited cell proliferation, arrested the cell cycle in S phase, induced ROS, localized in lysosomes, and weakly inhibited Topo IIα.

Conclusions:

• Carborane modification yields acridine analogs with distinct DNA-binding modes and potent anticancer properties.
• Compound 30 represents a promising DNA-targeting anticancer agent with multiple mechanisms of action.
• The study highlights the potential of carborane-acridine conjugates in cancer therapy research.